country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-138298

Copy Link Print Information

Trastuzumab deruxtecan (solution)

(Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution))

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.20%
CAS. Nr.: 1826843-81-5
Molecular Weight:153000 (average)

Speicherung:

-80°C, protect from light

Trastuzumab deruxtecan (solution) Chemical Structure

CAS. Nr.: 1826843-81-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (9)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle EGFR Isoform-spezifische Produkte anzeigen :

In Vitro

Trastuzumab deruxtecan (1 pM-10 nM; 5 days) (solution) inhibits the growth of HER2-positive KPL-4 cells, with an IC₅₀ of 109.7 pM^[2].
Trastuzumab deruxtecan (10 nM; 5 days) (solution) shows bystander killing effects in HER2-negative MDA-MB-468 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

KPL-4 and MDA-MB-468 cells
Concentration:

1, 10, 100, 1000, 10000 pM
Incubation Time:

5 days
Result:

Killed HER2-positive KPL-4 cells only.

In Vivo

Trastuzumab deruxtecan (3 mg/kg; a single i.v.) (solution) shows antitumor activity against not only HER2-positive tumors but also HER2-negative tumors under the co-inoculated condition^[2].
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) (solution) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female BALB/c nude mice injected with NCI-N87 and MDA-MB-468-Luc cells^[2]
Dosage:

3 mg/kg
Administration:

A single i.v.
Result:

Almost all of the HER2-positive and HER-negative cells disappeared and there were little or no cancer cells remaining in the tumors.

Chemical Information

CAS. Nr. 1826843-81-5
Appearance Liquid
Molecular Weight 153000 (average)
Color Colorless to light yellow
SMILES

[Trastuzumab deruxtecan (solution)]
Synonyms

T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Versand

Shipping with dry ice.
Speicherung

-80°C, protect from light

Publications (9)

All Cell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cancer Discov

HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies. [Abstract]

2026 Apr 2. PMID: 41925564
Mol Cancer Ther

Antibody-drug-conjugates prepared with Peptide Asparaginyl Ligases achieve strong in vitro and in vivo anti-tumor activity. [Abstract]

2026 Mar 26. PMID: 41889275
Sci Rep

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates. [Abstract]

2026 May 7. PMID: 42098228
Cancers (Basel)

Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy. [Abstract]

2026 Mar 19;18(6):997. PMID: 41899598
Biochem Biophys Res Commun

3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer. [Abstract]

2024 Jun 11:725:150255. PMID: 38897043

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Trastuzumab deruxtecan (1 μg/mL; 120 h). H2170 was treated with the indicated drugs and concentrations. Cell viability was measured by CellTiter-Glo assay or ONE-Glo Luciferase Assay.

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Trastuzumab deruxtecan (0-10 μg/mL; 72 h). JFCR-007 Luc-ZsG-positive cells were treated with T-DXd for 72 h in each co-culture conditions. Cell viability was measured by ONE-Glo Luciferase Assay.

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Trastuzumab deruxtecan (0-10 μg/mL; 120 h). The indicated cells were treated with serially diluted T-DXd for 120 h in a 2D culture condition.

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

JFCR-007 was treated with or without T-DXd (10 μg/mL) for 120 h in spheroid condition.

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Trastuzumab deruxtecan (1 μg/mL; 120 h). JFCR-007 was treated with the indicated drugs and concentrations. Cell viability was measured by CellTiter-Glo assay or ONE-Glo Luciferase Assay.
bioRxiv

2026 Jun 19.
bioRxiv

2026 May 27.
Saint Joseph University

2026.
Biomed Pharmacother

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]

2023 Jul:163:114751. PMID: 37105073

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645. [Content Brief]

[2]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518. [Content Brief]

[3]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [Content Brief]

[4]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Trastuzumab deruxtecan (solution)

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (9)
Reinheit & Dokumentation
Verweise

1/16
1/16

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Customer Validation
Trastuzumab deruxtecan (1 μg/mL; 120 h). H2170 was treated with the indicated drugs and concentrations. Cell viability was measured by CellTiter-Glo assay or ONE-Glo Luciferase Assay.
1/16

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Customer Validation
Trastuzumab deruxtecan (0-10 μg/mL; 72 h). JFCR-007 Luc-ZsG-positive cells were treated with T-DXd for 72 h in each co-culture conditions. Cell viability was measured by ONE-Glo Luciferase Assay.
1/16

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Customer Validation
Trastuzumab deruxtecan (0-10 μg/mL; 120 h). The indicated cells were treated with serially diluted T-DXd for 120 h in a 2D culture condition.
1/16

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Customer Validation
JFCR-007 was treated with or without T-DXd (10 μg/mL) for 120 h in spheroid condition.
1/16

Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255. [Abstract]

Customer Validation
Trastuzumab deruxtecan (1 μg/mL; 120 h). JFCR-007 was treated with the indicated drugs and concentrations. Cell viability was measured by CellTiter-Glo assay or ONE-Glo Luciferase Assay.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Trastuzumab deruxtecan (solution)

Publications Citing Use of MedChemExpress (MCE) Trastuzumab deruxtecan (solution)

Alle EGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (9)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Trastuzumab deruxtecan (solution) Related Classifications

HY-138298 Related Classifications